In what is believed to be the first study of its kind, researchers at the University of Colorado, Denver will study the genes of those with a kind of epilepsy called Dravet Syndrome who have been treated with a strain of medical marijuana known as Charlotte’s Web. The study will attempt to determine if specific genetic components can explain why some epilepsy patients see positive results from ingesting Charlotte’s Web, while others do not.
The new study will recruit epilepsy patients who have already taken Charlotte’s Web. The patients will be divided into two groups—those who have seen seizure activity reduced by at least 50 percent on Charlotte’s Web and those who have had less dramatic or no results from taking the marijuana oil. Genetic analysis of the patients in both groups will then be performed in hopes of discovering what genetic components may cause a patient to be responsive to medical marijuana. Interventional studies, in which patients would be given Charlotte’s Web to measure its efficacy, are far more difficult to conduct. “That would be the Holy Grail,” says Maa.
Still, researchers on the UC Denver team will collect data on dosages used by patients in the study, for example, which could allow for further research down the line. “The more data we are able to collect in a large sample, the closer to the truth we will get,” says Maa. He says the study could allow children with Dravet Syndrome to be genetically screened before taking Charlotte’s Web so parents could know ahead of time if their children would benefit. It’s possible to conduct the study in Colorado because Charlotte’s Web is grown there legally and is home to many families who have moved to the state to specifically to access the marijuana strain.
Continue Reading at TIME: http://time.com/3264691/medical-marijauna-epilepsy-research-charlottes-web-study/